Sitagliptin Potentiates the Anti-Neoplastic Activity of Doxorubicin in Experimentally-Induced Mammary Adenocarcinoma in Mice: Implication of Oxidative Stress, Inflammation, Angiogenesis, and Apoptosis

Sitagliptin Potentiates the Anti-Neoplastic Activity of Doxorubicin in Experimentally-Induced Mammary Adenocarcinoma in Mice: Implication of Oxidative Stress, Inflammation, Angiogenesis, and Apoptosis

Sitagliptin (STG) is a highly selective dipeptidyl peptidase-4 inhibitor recently used in the treatment of type 2 diabetes. The current study aimed to investigate the anti-neoplastic effect of STG alone and in combination with Doxorubicin (Dox), a known chemotherapeutic agent but with ominous side e...

Full description

Bibliographic Details
Main Authors: Mohamed M. Salama, Randa A. Zaghloul, Rania M. Khalil, Mamdouh M. El-Shishtawy
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Scientia Pharmaceutica
Subjects:
Ehrlich solid carcinoma
sitagliptin
doxorubicin
β-catenin
cyclin-D1
survivin
Online Access:https://www.mdpi.com/2218-0532/90/3/42

Internet

https://www.mdpi.com/2218-0532/90/3/42

Similar Items